{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:31:22Z","timestamp":1778761882784,"version":"3.51.4"},"reference-count":64,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1517\/14796694.1.3.297","type":"journal-article","created":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T13:47:27Z","timestamp":1120744047000},"page":"297-306","source":"Crossref","is-referenced-by-count":17,"title":["Evolving Role of Rituximab in the Treatment of Patients with Non-Hodgkin's Lymphoma"],"prefix":"10.1080","volume":"1","author":[{"given":"Bertrand B","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Traull\u00e9","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon,Hematology Department,\rCH Lyon-Sud,\r69495\rPierre-Benite,\rFrance Tel.: ; Fax: ; ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,12,2]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-03-0250"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1352"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_3_1_10_1","first-page":"170a","article-title":"Evidence for Fc\u03b3 receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immunochemotherapy.","volume":"104","author":"Boettcher S","year":"2004","unstructured":"Boettcher S , PottC, RitgenM, HiddemannW, UnterhaltM, KnebaM: Evidence for Fc\u03b3 receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immunochemotherapy.Proc. Am. Soc. Hemat. Blood104, 170a[Abstract] (2004) .","journal-title":"Proc. Am. Soc. Hemat. Blood"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_3_1_12_1","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.","volume":"20","author":"Alas S","year":"2000","unstructured":"Alas S , BonavidaB, EmmanouilidesC: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.Antican. Res.20(5A), 2961\u20132966 (2000).","journal-title":"Antican. Res."},{"issue":"13","key":"e_1_3_1_13_1","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of gtranscription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine\/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs.","volume":"61","author":"Alas S","year":"2001","unstructured":"Alas S , BonavidaB: Rituximab inactivates signal transducer and activation of gtranscription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine\/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs.Cancer Res.61(13), 5137\u20135144 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1392"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207336"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437875100"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30145"},{"key":"e_1_3_1_19_1","first-page":"207\u2013208 [Abstra","volume-title":"Bone Marrow Transplamt","author":"Lim SH","year":"2004","unstructured":"Lim SH , ZhangY, WangZet al.: Maintenance rituximab after autologous stem cell transplant for high-risk B cell lymphoma induces prolonged and severe hypogammaglobulinemia.Bone Marrow Transplamt35(2),207\u2013208 [Abstract](2004)."},{"issue":"5","key":"e_1_3_1_20_1","first-page":"74","article-title":"Preclinical and Phase I and II trials of rituximab.","volume":"26","author":"Maloney DG","year":"1999","unstructured":"Maloney DG : Preclinical and Phase I and II trials of rituximab.Semin. Oncol.26(5 Suppl. 14), 74\u201378 (1999).","journal-title":"Semin. Oncol."},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_3_1_23_1","first-page":"467","volume-title":"Hematol. J.","author":"Lemieux B","year":"2004","unstructured":"Lemieux B , BouafiaF, ThieblemontCet al.: Second treatment with rituximab in B cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud.Hematol. J.5(6), 467\u2013471 (2004)."},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.005"},{"key":"e_1_3_1_27_1","article-title":"Maximizing therapeutic benefit of rituximab: Maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma. A randomized Phase II trial of the Minnie Pearl Cancer Research Network.","author":"Hainsworth JD","year":"2005","unstructured":"Hainsworth JD , LitchyS, ShafferDW, LackeyVL, GrimaldiM, GrecoFA: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma. A randomized Phase II trial of the Minnie Pearl Cancer Research Network.J. Clin. Oncol. 23, 1088\u20131095 (2005).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_3_1_31_1","first-page":"4111","volume-title":"J. Clin. Oncol.","author":"Czuczman MS","year":"2004","unstructured":"Czuczman MS , WeaverR, AlkuzwenyB, BerlfeinJ, Grillo-LopezAJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.J. Clin. Oncol.4111\u20134116 (2004)."},{"key":"e_1_3_1_32_1","doi-asserted-by":"crossref","unstructured":"Marcus R ImrieK BelchA et al. : CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Proc. Am. Soc. Hemat. Blood 104 1417\u20131423 [Abstract] (2004).","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_3_1_33_1","first-page":"104a [Abstract","volume":"102","author":"Hiddemann W","year":"2003","unstructured":"Hiddemann W , DreylingMH, ForstpointnerRet al.: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma results of a prospective randomized trial of the German low grade Lymphoma Study Group (GLSG). Blood102,104a [Abstract 352] (2003).","journal-title":"Blood"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.584.584"},{"key":"e_1_3_1_35_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.160.160","volume":"104","author":"Salles G","year":"2004","unstructured":"Salles G , FoussardC, MounierNet al.: Rituximab added to CHVP + IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomized trial. Blood104(11) [Abstract 160] (2004).","journal-title":"Blood"},{"key":"e_1_3_1_36_1","author":"Hiddemann W","year":"2004","unstructured":"Hiddemann W , DreylingM, UnterhaltMet\u00a0al.: Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treament failure compared to CHOP alone in mantle cell lymphoma: results of a prospective ransomized trial of the German Low Grade Lymphomas Study Group. Proc. Am. Soc. Clin. Oncol. [Abstract 6501] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_3_1_38_1","first-page":"169","article-title":"Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed \/resistant follicular non-Hodgkin's lymphoma: A Phase III randomized intergroup clinical trial.","volume":"104","author":"Van Oers MHJ","year":"2004","unstructured":"Van Oers MHJ , VanGlabbeke M, TeodorovicIet al.: Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed \/resistant follicular non-Hodgkin's lymphoma: A Phase III randomized intergroup clinical trial.Blood104,169a [Abstract 586] (2004).","journal-title":"Blood"},{"key":"e_1_3_1_39_1","article-title":"Results of E1496: A Phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma.","volume":"556","author":"Hochster HS","year":"2004","unstructured":"Hochster HS , WellerE, RyanTet al.: Results of E1496: A Phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma.Proc. Am. Soc. Clin. Oncol.556a [Abstract 6502] (2004).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"7","key":"e_1_3_1_40_1","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-\u03b12a.","volume":"6","author":"Davis TA","year":"2000","unstructured":"Davis TA , MaloneyDG, Grillo-LopezAJet\u00a0al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-\u03b12a.Clin. Can. Res.6(7), 2644\u20132652 (2000).","journal-title":"Clin. Can. Res."},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.32747"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0525"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402424"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"},{"key":"e_1_3_1_46_1","first-page":"569","volume-title":"Blood","author":"Keating M","year":"2003","unstructured":"Keating M , ManshouriT, O'BrienSet al.: A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukaemia.Blood2, 569 (2003)."},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000123555"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_3_1_54_1","first-page":"556","volume-title":"Proc. Am. Soc. Clin. Oncol.","author":"Pfreundschuh MG","year":"2004","unstructured":"Pfreundschuh MG , Tr\u00fcmperL, MaDet al.: Randomized intergroup trial of first-line treatment for patients \u2264\u00a060 years with diffuse large B cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab \u2013 early stopping after the first interim analysis.Proc. Am. Soc. Clin. Oncol.23, 556 [Abstract 6500] (2004)."},{"key":"e_1_3_1_55_1","volume-title":"Blood","author":"Habermann TM","year":"2004","unstructured":"Habermann TM , WellerE, MorrisonVAet\u00a0al.: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update.Blood102, 6a [Abstract 8] (2004)."},{"key":"e_1_3_1_56_1","first-page":"29a","article-title":"Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC).","volume":"102","author":"Sehn LH","year":"2003","unstructured":"Sehn LH , DonaldsonJ, ChhanabhaiMet\u00a0al.: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC).Blood102 (Suppl. 1), 29a (2003).","journal-title":"Blood"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2644"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/11.suppl_1.S113"},{"key":"e_1_3_1_59_1","first-page":"22, 564","volume-title":"Proc. Am. Soc. Clin. Oncol.","author":"Kaplan LD","year":"2004","unstructured":"Kaplan LD , ScaddenDT: For the AIDS Malignancies Consortium. No benefit from rituximab in a randomized Phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS malignancies consortium study 010.Proc. Am. Soc. Clin. Oncol.22, 564 [Abstract 2268] (2004)."},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh090"},{"issue":"4","key":"e_1_3_1_62_1","first-page":"227","article-title":"Rituximab in stem cell transplantation for aggressive lymphoma.","volume":"3","author":"Horwitz SM","year":"2004","unstructured":"Horwitz SM , HorningSJ: Rituximab in stem cell transplantation for aggressive lymphoma.Curr. Hematol. Rep.3(4), 227\u2013229 (2004).","journal-title":"Curr. Hematol. Rep."},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.008"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704467"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_1_66_1","first-page":"6a","article-title":"Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL).","volume":"1","author":"Habermann TM","year":"2003","unstructured":"Habermann TM , WellerEA, MorrisonVAet\u00a0al.: Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL).Blood 102(Suppl.1), 6a (2003).","journal-title":"Blood"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14796694.1.3.297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:48Z","timestamp":1719124848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14796694.1.3.297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1517\/14796694.1.3.297"],"URL":"https:\/\/doi.org\/10.1517\/14796694.1.3.297","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}